This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
McKesson (MCK) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
McKesson's (MCK) fiscal second-quarter 2022 results benefit from substantial growth in the Medical-Surgical Solutions business.
Hologic (HOLX) Q4 Earnings Surpass Estimates, 2022 View Dull
by Zacks Equity Research
Impressive performance by the Breast Health and GYN Surgical segments drives Hologic's (HOLX) fiscal fourth-quarter revenues.
NextGen Healthcare (NXGN) Gains 9.7% Since Q2 Earnings Beat
by Zacks Equity Research
NextGen Healthcare's (NXGN) fiscal second-quarter earnings reflect strong segmental performance.
Chemed (CHE) Q3 Earnings Beat Estimates, Full-Year EPS View Up
by Zacks Equity Research
Chemed (CHE) reports better-than-expected earnings and revenues in the third-quarter 2021, with a solid performance by the Roto-Rooter segment driving the top line.
OPKO Health's (OPK) Q3 Earnings, Revenues Top Estimates
by Zacks Equity Research
OPKO Health's (OPK) third-quarter results benefit from strength in its Pharmaceuticals segment, backed by robust RAYALDEE sales.
Integer Holdings (ITGR) Beats on Q3 Earnings, Ups 2021 EPS View
by Zacks Equity Research
Integer Holdings' (ITGR) third-quarter results reflect robust segmental performances along with strength in the majority of the product lines.
Merit Medical's (MMSI) Q3 Earnings, Revenues Top Estimates
by Zacks Equity Research
Merit Medical (MMSI), in the third quarter, benefits from revenue growth in its Cardiovascular segment, and from the majority of the product categories within its Cardiovascular unit.
Cerner (CERN) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Cerner's (CERN) third-quarter results benefit from gains across four of its business units.
Bio-Rad (BIO) Q3 Earnings Surpass Estimates, 2021 View Raised
by Zacks Equity Research
Strength in the Life Science and Clinical Diagnostics segments drove Bio-Rad's (BIO) revenues in the third quarter.
DexCom (DXCM) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
DexCom's (DXCM) third-quarter results benefit from domestic and international revenue growth and solid new customer additions.
Stryker (SYK) Earnings and Revenues Miss Estimates in Q3
by Zacks Equity Research
Despite pandemic-led disruptions, Stryker's (SYK) third-quarter earnings reflect strong performance across Orthopaedics, MedSurg and Neurotechnology and Spine segments.
ResMed (RMD) Q1 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
ResMed (RMD) reports better-than-expected earnings and revenues with robust demand for sleep and respiratory care devices driving Q1 top line.
DaVita (DVA) Beats on Q3 Earnings, Narrows 2021 EPS View
by Zacks Equity Research
DaVita's (DVA) strength in dialysis patient service revenues drives its Q3 top line.
Teleflex (TFX) Q3 Earnings Top Estimates, Full-Year EPS View Up
by Zacks Equity Research
Teleflex (TFX) reports better-than-expected earnings and revenues with strong geographical performance driving the top line in third-quarter 2021.
Thermo Fisher (TMO) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Thermo Fisher (TMO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Has Thermo Fisher Scientific (TMO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (TMO) Outperforming Other Medical Stocks This Year?
Thermo Fisher (TMO) Beats on Q3 Earnings, Raises 2021 View
by Zacks Equity Research
Thermo Fisher (TMO) delivers a strong quarterly performance, leveraging on a significant rebound in its base business.
Here's How Much a $1000 Investment in Thermo Fisher Scientific Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Thermo Fisher Scientific (TMO) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of 23.34% and 11.96%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: Capital One Financial, Thermo Fisher Scientific, Aflac, DexCom and Exxon Mobil
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Capital One Financial, Thermo Fisher Scientific, Aflac, DexCom and Exxon Mobil
Medical Products Stock Q3 Earnings on Oct 27: TMO, EW & More
by Urmimala Biswas
With the pandemic raging on, testing, vaccine and therapeutic makers witness huge market adoption of their COVID-related support products in Q3.
5 S&P 500 Stocks to Buy Ahead of Q3 Earnings This Week
by Nalak Das
Five big S&P 500 companies (market capital > $45 billion) are slated to release third-quarter earnings results this week. These are: COF, DXCM, XOM, AFL and TMO.
Abbott's (ABT) Organic Sales Grow Amid Spike in COVID Cases
by Zacks Equity Research
Within Nutrition, the robust year-over-year performance of Abbott's (ABT) U.S. pediatric and international adult nutrition arms drives the company in the third quarter.
Why Thermo Fisher (TMO) Might Surprise This Earnings Season
by Zacks Equity Research
Thermo Fisher (TMO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
STERIS (STE) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Strong performance by the Healthcare, AST and Life Sciences segments is driving the top line for STERIS (STE).